Rilvegostomig + Durvalumab + Gemcitabine/Cisplatin
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Biliary Tract Cancer
Conditions
Biliary Tract Cancer
Trial Timeline
Dec 4, 2025 → Jul 4, 2029
NCT ID
NCT07221253About Rilvegostomig + Durvalumab + Gemcitabine/Cisplatin
Rilvegostomig + Durvalumab + Gemcitabine/Cisplatin is a phase 3 stage product being developed by AstraZeneca for Biliary Tract Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07221253. Target conditions include Biliary Tract Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07221253 | Phase 3 | Recruiting |
Competing Products
20 competing products in Biliary Tract Cancer